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Magnetic Resonance Imaging in Cardiac Amyloidosis*
Dudley J. Pennell, MD,† Alicia M. Maceira, MD‡
London, United Kingdom; and Valencia, SpainThe amyloidoses are a group of uncommon systemic
diseases characterized by the extracellular deposition
of pathologic insoluble amyloid protein in organs and
tissues. The are 4 main types of amyloidosis: primary
(AL, the most prevalent type), familial, secondary, and
senile. Each of them has its own physiopathology,
distinctive features, and variable cardiac involvement.
The symptoms of cardiac amyloidosis include atrial,
atrioventricular, and ventricular conduction distur-
bances, ventricular and supraventricular arrhythmias,
orthostatic symptoms, restrictive cardiomyopathy, an-
gina, and heart failure.
See page 1369
New therapies for cardiac amyloidosis have been
recently introduced with promising results, and
therefore, early diagnosis of cardiac amyloidosis is
important, but can be very challenging. Endomyo-
cardial biopsy (EMB) remains the gold standard
diagnostic method (1), although clinically signifi-
cant amyloid can be missed with small biopsies
because of heterogeneous deposition. In practice,
noninvasive tests are widely used to diagnose amy-
loidosis, including electrocardiography and echo-
cardiography (2). Electrocardiography has limited
diagnostic accuracy, which increases when it is
combined with echocardiography. Echocardiogra-
phy has some diagnostic limitations, however, par-
ticularly if left ventricular hypertrophy from other
causes is present, and is usually normal until the
patient is symptomatic. Finally, neither electrocar-
diography nor echocardiography can confirm the
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Cardiovascular Magnetic Resonance Unit, Royal Brompton
Hospital, London, United Kingdom; and the ‡Cardiac Imaging Unit,
ERESA, Valencia, Spain. Dr. Pennell is a consultant for and receives
research support from Siemens.diagnosis by itself, and they cannot confirm amy-
loidosis type.
Diagnosis
Late gadolinium-enhanced cardiovascular magnetic
resonance (LGE-CMR) has value in the diagnosis
of amyloid cardiomyopathy. Gadolinium chelates
distribute in the extracellular space that is expanded
by amyloid infiltration, leading to signal enhance-
ment. The blood pool is unusually dark in these
patients, probably reflecting high tissue uptake and
fast blood pool washout. LGE was shown in 69% of
patients with a characteristic global subendocardial
diffuse pattern that agreed with the transmural
histological distribution of amyloid protein in the
myocardium and correlated with morphological
markers of increased amyloid load (3). Further-
more, a T1 mapping method revealed abnormal
gadolinium kinetics. An optimized threshold (191
ms at 4 min) between myocardial and blood showed
an 88% accuracy in the diagnosis of cardiac amy-
loidosis. A patchy pattern of LGE can also occur.
Other studies have confirmed the value of LGE for
diagnosis (4,5). Although there is agreement that
LGE-CMR is useful in diagnosing cardiac amy-
loidosis, it has not been compared with traditional
noninvasive markers. In this issue of iJACC, Austin
et al. (6) report their study of diagnostic accuracy in
38 patients with EMB, LGE-CMR, clinical assess-
ment, electrocardiography (ECG), and echocardi-
ography (2-dimensional and Doppler). Of the 38
patients, 17 had EMB-proven cardiac amyloidosis.
When compared with Carroll’s low-voltage criteria,
deceleration time 150 ms on Doppler, and New
York Heart Association functional class status,
LGE-CMR was the most accurate predictor of
EMB-positive cardiac amyloidosis, with sensitivity,
specificity, and positive and negative predictive values
of 88%, 95%, 93%, and 90%, respectively, within the
range of previously published reports and significantly
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1379igher than for the other tests. Despite these good
esults, the authors acknowledge that LGE-CMR
ay also have pitfalls. An early patchy subendocardial
GE, asymmetrical hypertrophy, or the coexistence of
ther conditions such as ischemic heart disease may
ead to a false negative interpretation, as it was in the
ase with 2 patients in the present study. In addition,
he LGE technique can be challenging in amyloidosis,
nd care must be taken when acquiring the images in
rder not to get confusing results, and it is here where
ssessment of T1 kinetics can be helpful.
rognosis
he prognosis of amyloidosis is generally poor if
ntreated, and cardiac involvement is a marker of poor
utcome. Thus, median survival for AL amyloidosis is
3 months without therapy and 17 months with
elphalan, whereas only 5% of patients survive more
han 10 years. When cardiac involvement is present,
urvival rate is even worse, with mean survival of 6
onths after the onset of congestive heart failure.
herapy with high-dose intravenous melphalan plus
utologous peripheral blood stem-cell transplantation
as shown a 40% complete remission at 1 year and
mproved median survival to 4.6 years, which again
ecreases to 1.6 years if there is cardiac involvement.
ardiac transplantation in AL amyloid has shown 1-
nd 5-year survival rates of 60% and 30%, respectively.
or familial amyloidosis, survival may be up to 15
ears, and liver transplantation is nowadays the only
efinitive therapeutic intervention, combined or not
ith heart transplant. Senile amyloidosis has a better
rognosis, with a median survival rate of 5 years.
inally, for AA amyloidosis, prognosis is usually
etermined by the underlying chronic disease, with a
edian survival from diagnosis of roughly 10 years.
A large number of prognostic parameters in amy-
oidosis have been reported in the past, including the
resence of heart failure or syncope, elevation of
roponins and N-terminal pro–B-type natriuretic pep-
ide, complex ventricular arrhythmia on ambulatory
CG monitoring, low voltage on the ECG, and
ulmonary hypertension (7). There are also a number
f echocardiography-derived prognostic markers such
s left ventricular ejection fraction, left ventricular wall
hickness (inversely related to survival), right ventric-
lar dilation, restrictive hemodynamics, myocardial
erformance index, and abnormalities in cycle-
ependent variation of myocardial integrated back-
catter (8,9). Currently, there is little agreement onecent study showed the only significant predictors of
urvival were left ventricular ejection fraction, low-
oltage on the ECG, and etiology of amyloidosis.
MR has shown prognostic utility in amyloidosis
10). No differences in survival were seen according to
he presence of LGE, but T1 kinetics showed that an
ntramyocardial T1 gradient 23 ms at 2 min and
ubepicardial-blood T1 difference 80 ms had an
5% and 90% accuracy, respectively, for predicting
utcome. A likely explanation for the discrepancy
etween LGE and T1 kinetics is the superior discrim-
nation by T1 kinetics for the severity and transmu-
ality of the myocardial amyloid burden. The in-
ramyocardial T1 gradient (subepicardium minus
ubendocardium T1), for which higher values indicate
ess gadolinium in the epicardium, and subepicardial
inus blood T1 difference (again reflecting lower
picardial gadolinium uptake) were both higher in
atients who survived. This is explained by the usual
attern of amyloid deposition in the myocardium,
hich is predominantly subendocardial with lower
ardiac amyloid burden. The Austin et al. (6) report
lso assessed the prognostic value of LGE-CMR and
ound that it was the only significant predictor of
-year mortality, whereas no echocardiographic pa-
ameter was predictive. There is a possible explanation
or this discrepancy with previous CMR results. At 1
ear, they found only 9 deaths (36%) among the
iopsy-positive patients, which is better than previous
urvival figures. This may reflect either a different
opulation with earlier disease, or the effect of recently
mplemented therapeutic protocols that have affected
urvival. It is plausible that LGE may have significant
rognostic utility in early-stage amyloidosis, whereas
or a more advanced stage of the disease, T1 kinetics
ay be more useful.
In summary, there is agreement on the diagnostic
alue of CMR in cardiac amyloidosis. Furthermore,
GE-CMR might help detect cardiac involvement in
ystemic amyloidosis when cardiac changes are not
pparent in echocardiography. Screening of subclinical
ardiac involvement may become possible should
GE prove to have adequate sensitivity and specificity
n detecting amyloid infiltration. CMR also appears to
e useful to assess prognosis. Further comparative
tudies are needed in well-defined clinical cohorts, and
his will require a multicenter approach.
eprint requests and correspondence: Prof. Dudley J. Pen-
ell, Cardiovascular Magnetic Resonance Unit, Royal
rompton Hospital, Sydney Street, London SW3 6NP,hich parameters are most predictive of outcome. A United Kingdom. E-mail: d.pennell@ic.ac.uk.
R1
K
y
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 2 , 2 0 0 9
D E C E M B E R 2 0 0 9 : 1 3 7 8 – 8 0
Pennell and Maceira
Editorial Comment
1380E F E R E N C E S
1. Falk RH. Diagnosis and management
of the cardiac amyloidoses. Circula-
tion 2005;112:2047–60.
2. Rahman JE, Helou EF, Gelzer-Bell
R, et al. Noninvasive diagnosis of
biopsy-proven cardiac amyloidosis.
J Am Coll Cardiol 2004;43:410–5.
3. Maceira AM, Joshi J, Prasad SK, et al.
Cardiovascular magnetic resonance in
cardiac amyloidosis. Circulation 2005;
111:186–93.
4. Ruberg FL, Appelbaum E, Davidoff
R, et al. Diagnostic and prognostic
utility of cardiovascular magnetic res-
onance imaging in light-chain cardiac
amyloidosis. Am J Cardiol 2009;103:
544–9.5. Vogelsberg H, Marholdt H, Deluigi
CC. Cardiovascular magnetic reso-
nance in clinically suspected cardiac
amyloidosis: noninvasive imaging
compared to endomyocardial biopsy.
J Am Coll Cardiol 2008;51:1022–30.
6. Austin BA, Tang WHW, Rodriguez
ER, et al. Delayed hyper-enhancement
magnetic resonance imaging provides
incremental diagnostic and prognostic
utility in suspected cardiac amyloido-
sis. J Am Coll Cardiol Img 2009;2:
1369–77.
7. Kristen AV, Perz JB, Schonland SO,
et al. Noninvasive predictors of sur-
vival in cardiac amyloidosis. Eur
J Heart Fail 2007;9:617–24.
8. Klein Al, Hatle LK, Taliercio CP, et
al. Prognostic significance of Dopp-
ler measures of diastolic function in dcardiac amyloidosis. A Doppler echo-
cardiographic study. Circulation 1991;
83:808–16.
9. Tei C, Dujardin KS, Hodge DO,
Kyle RA, Tajik AJ, Seward JB. Dopp-
ler index combining systolic and dia-
stolic myocardial performance: clinical
value in cardiac amyloidosis. J Am
Coll Cardiol 1996;28:658–64.
0. Maceira AM, Prasad SK, Hawkins PN,
Roughton M, Pennell DJ. Cardiovascu-
lar magnetic resonance and prognosis in
cardiac amyloidosis. J Cardiovasc Magn
Reson 2008;10:54–65.
ey Words: magnetic resonance
amyloidosis y heart yiagnosis y prognosis.
